Shares of the power management company jumped after it reported second-quarter results that topped analyst expectations and issued an upbeat forecast, fueled by demand in its core electrical and aerospace segments.
Shares of the Swiss specialty chemicals firm surged after its second-quarter earnings beat analyst estimates by 13% and a Dutch court dismissed a €1 billion damages claim from Shell.
The U.S. refiner's board of directors approved a significant increase to its share repurchase authorization, signaling a strong commitment to shareholder returns amid favorable market conditions.
Strategists at Barclays argue that with increasing bond market volatility and higher real yields, strong corporate earnings are now the crucial factor needed to support further gains in the stock market.
Ingram Micro shares are declining after the company reported a significant cash outflow and issued a weaker-than-expected Q3 earnings forecast, overshadowing record second-quarter revenue.
Shares of pharmaceutical giant AbbVie fell after its second-quarter earnings report, as investors took profits following a significant pre-earnings rally despite the company having previously disclosed one-time charges.
The pharmaceutical giant reduced its full-year earnings forecast to reflect its pending $10.9 billion acquisition of Apogee Therapeutics, while strong sales from its immunology drugs drove second-quarter results above analyst expectations.
Boston Scientific shares are extending losses after the medical device maker cut its full-year financial outlook for the second straight quarter, overshadowing a Q2 earnings beat and triggering multiple analyst price target reductions.
The lender raised its full-year return on tangible equity forecast to over 14% and increased its interim dividend after first-half profit beat expectations, driven by a sharp drop in impairments.
